Back to search

Boston University

Efficiency of siRNA in silencing Braf-V600E mutated osteoclasts in a mouse model of histiocytosis-like disease with bone involvement

Abstract

dc:description.abstract

Histiocytosis is a group of disorders characterized by the accumulation of aberrant hemopoietic cells that result in inflammatory lesions capable of subsequent damage in multiple organ systems such as the liver, lungs, lymph nodes, spleen, and bone. This disorder results from a mutation in the BRAF gene, a serine/threonine protein kinase that is involved in intracellular signaling pathways critical for cell proliferation and differentiation as well as survival. These mutations result in constitutive activation of the BRAF protein, causing aberrant hyperactivation of this signaling pathway. Langerhans Cell Histiocytosis is a disease resulting from aberrant Langerhans cells affecting multiple organs, including skin, lung, brain, bone, and so forth. Patients that have LCH with bone involvement present with an accumulation of hyperactive osteoclasts and bone resorbing cells, resulting in painful osteolytic lesions across the skeletal system. Current treatments such as BRAF and osteoclast inhibitors demonstrate the capability to manage the disease in the short term but not without long-term side effects, such as drug toxicity or growth defects on longitudinal bone, that predominantly affect children. Our laboratory is working on testing gene silencing (siRNA) of the BRAF mutation to restore normal bone resorption in mouse models of LCH. Our preliminary results first focused on establishing optimal concentrations of siRNA (control) in vitro in osteoclast cultures from wild-type or Braf-mutated bone marrow osteoclast progenitor cells. Then we tested siRNA against the Braf-V600E mutation in these cultures. Results demonstrated that, unlike the control, siRNA-BrafV600E cytotoxicity is higher when compared to the same concentrations utilized for the siRNA control; therefore, siRNA-BrafV600E treatment warrants future investigation.

Degree

thesis:*
Name thesis:degree_name
Master of Science
Level thesis:degree_level
masters
Discipline thesis:degree_discipline
Medical Sciences
Grantor
Boston University
Year dc:date.issued
2025

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Rodriguez, Jorge H.
Advisors dc:contributor.advisor
  • Gerstenfeld, Louis C.
  • Jacome-Galarza, Christian E.
ORCID dc:identifier.orcid

Subjects

dc:subject × 1

Rights

Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
https://hdl.handle.net/2144/52417

Chain of custody

source
Harvested from
Boston University
Base URL
open.bu.edu/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Rodriguez, Jorge H.. Efficiency of siRNA in silencing Braf-V600E mutated osteoclasts in a mouse model of histiocytosis-like disease with bone involvement. masters thesis, Boston University, 2025. https://hdl.handle.net/2144/52417